Partner Therapeutics Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
187
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$60M
- Investors
-
3
Partner Therapeutics General Information
Description
Developer of a biopharmaceutical company designed to assist in oncology treatment. The company's drugs are developed focusing on developing and commercializing approved and late-stage therapies that improve treatment outcomes and reduce the total cost of care for cancer, enabling patients to get effective oncology treatments for any stage.
Contact Information
Website
www.partnertx.comCorporate Office
- 19 Muzzey Street
- Lexington, MA 02421
- United States
Corporate Office
- 19 Muzzey Street
- Lexington, MA 02421
- United States
Partner Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Early Stage VC (Series A) | 01-Feb-2018 | $60M | Completed | Generating Revenue |
Partner Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Partner Therapeutics Comparisons
Industry
Financing
Details
Partner Therapeutics Competitors (117)
One of Partner Therapeutics’s 117 competitors is Nanoviricides, a Corporation company based in Shelton, CT.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nanoviricides | Corporation | Shelton, CT | ||||
| Ability Pharma | Private Equity-Backed | Cerdanyola, Spain | ||||
| Palobiofarma | Venture Capital-Backed | Barcelona, Spain | ||||
| Day One Biopharmaceuticals | Formerly VC-backed | Brisbane, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA |
Partner Therapeutics Patents
Partner Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4784160-A2 | Effects of gm-csf addition on humoral modulation and fcgr2b binding in allergy, infection and immunity | Pending | 29-Sep-2023 | ||
| WO-2025072659-A2 | Effects of gm-csf addition on humoral modulation and fcgr2b binding in allergy, infection and immunity | Inactive | 29-Sep-2023 | ||
| WO-2025072659-A3 | Effects of gm-csf addition on humoral modulation and fcgr2b binding in allergy, infection and immunity | Inactive | 29-Sep-2023 | ||
| EP-4704881-A2 | Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf) | Pending | 03-May-2023 | ||
| US-20260295009-A1 | Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf) | Pending | 03-May-2023 | A61K38/193 |
Partner Therapeutics Signals
Partner Therapeutics Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Adams Street Partners | PE/Buyout | Minority | ||
| MidCap Financial | Lender/Debt Provider | Minority | ||
| Perceptive Advisors | Venture Capital | Minority |
Partner Therapeutics Investments (1)
Partner Therapeutics’s most recent deal was a Corporate Asset Purchase with Immunex (Global rights to Leukine). The deal was made on 01-Feb-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Immunex (Global rights to Leukine) | 01-Feb-2018 | Corporate Asset Purchase | Buildings and Property |
Partner Therapeutics FAQs
-
When was Partner Therapeutics founded?
Partner Therapeutics was founded in 2017.
-
Where is Partner Therapeutics headquartered?
Partner Therapeutics is headquartered in Lexington, MA.
-
What is the size of Partner Therapeutics?
Partner Therapeutics has 187 total employees.
-
What industry is Partner Therapeutics in?
Partner Therapeutics’s primary industry is Drug Discovery.
-
Is Partner Therapeutics a private or public company?
Partner Therapeutics is a Private company.
-
What is the current valuation of Partner Therapeutics?
The current valuation of Partner Therapeutics is .
-
What is Partner Therapeutics’s current revenue?
The current revenue for Partner Therapeutics is .
-
How much funding has Partner Therapeutics raised over time?
Partner Therapeutics has raised $60M.
-
Who are Partner Therapeutics’s investors?
Adams Street Partners, MidCap Financial, and Perceptive Advisors have invested in Partner Therapeutics.
-
Who are Partner Therapeutics’s competitors?
Nanoviricides, Ability Pharma, Palobiofarma, Day One Biopharmaceuticals, and Genentech are some of the 117 competitors of Partner Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process